Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
VELDHOVEN, the Netherlands - ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program.
| Date | Total repurchased shares | Weighted average price | Total repurchased value |
| 26-Feb-18 | - | - | - |
| 27-Feb-18 | 26,637 | 161.63 | 4,305,284.85 |
| 28-Feb-18 | 49,000 | 161.93 | 7,934,768.60 |
| 1-Mar-18 | 20,000 | 157.45 | 3,149,000.00 |
| 2-Mar-18 | - | - | - |
ASML's current share buyback program was announced on 17 January 2018, and details are available on our website at https://www.asml.com/investors/share-buyback/en/s25436
This regular update of the transactions conducted under the buyback program is to be made public under the Market Abuse Regulation (Nr. 596/2014).
| Media Relations Contacts | Investor Relations Contacts |
| Monique Mols, phone +31 6 528 444 18 | Skip Miller, phone +1 480 235 0934 |
| Niclas Mika, phone +31 6 201 528 63 | Marcel Kemp, phone +31 40 268 6494 |
